BioCentury
ARTICLE | Clinical News

JZP-110: Phase III started

June 29, 2015 7:00 AM UTC

Jazz began the 6-week, double-blind, placebo-controlled, U.S. Phase III Study 14-004 to evaluate 75, 150 and 300 mg oral JZP-110 once daily in about 200 patients. In 2014, Jazz purchased from Aerial ...